-5%
Levodopa + Carbidopa + Entacapone is used for the treatment of Parkinson’s disease and its related motor symptoms.
- Do not discontinue abruptly — may trigger neuroleptic malignant syndrome (NMS) with symptoms like fever, muscle rigidity, confusion, and irregular heartbeat.
- Use cautiously in patients with heart disease, glaucoma, mental illness, stomach ulcers, liver or kidney disease, or arrhythmia.
- May cause drowsiness or dizziness — avoid driving or operating machinery until effects are known.
- Prolonged use may increase risk of nerve damage (neuropathy).
- Hallucinations may occur with long-term therapy.
- Not recommended in children; safety not established.
Carbidopa + Levodopa + Entacapone is a combination medicine used in the management of Parkinson’s disease, a progressive neurological disorder that affects movement. It helps relieve symptoms such as tremors, stiffness, spasms, difficulty in walking, and loss of coordination. The condition arises due to a decline in dopamine-producing neurons in the brain.
This preparation combines three agents that act synergistically:
- Levodopa – Converts into dopamine in the brain, restoring dopamine levels and improving motor control.
- Carbidopa – A decarboxylase inhibitor that prevents the premature breakdown of levodopa in the bloodstream, allowing more of it to reach the brain.
- Entacapone – A COMT (catechol-O-methyltransferase) inhibitor that prolongs levodopa’s action in the body, ensuring sustained relief from Parkinson’s symptoms.
Together, these agents improve movement, reduce stiffness, and help control involuntary movements.